Abstract
Scientific and technological progress in the life sciences and modern biotechnology is continuing at a breathtaking pace. At the same time, the potential implications for individuals and society are giving rise to intense debate. This article gives a background to the European Institute of Women’s Health (EIWH) and the work of the organisation in contributing to and developing policy at a European level. We will identify the policy issues related to gender-based healthcare research arising from the EU 6th Framework Programme for Research, which was introduced this year, and the implications for the EU Public Health Strategy. Additionally, the issues of personalised medicine and the promise of biotechnology for improved medicines and healthcare will be addressed from a gender perspective. What are the prospects in the medium and long term? How can we best address the ethical and socio-economic implications?
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
World Health Organization. Mainstreaming gender in health: the need to move forward. Madrid: World Health Organization, 2001
Eurostat. Luxembourg: Office for Official Publications of the European Communities, 1998
EIWH. Promoting gender equity in EU public health. Dublin: European Institute of Women’s Health, 2000
Eurostat. Luxembourg: Office for Official Publications of the European Communities, 1999
Macintyre S, Hunt K, Sweeting H. Gender differences in health: are things as simple as they seem? Soc Sci Med 1996; 42 (4): 617–24
EIWH. Women in Europe: towards healthy ageing. Dublin: European Institute of Women’s Health, 1996
Vademecum. Gender mainstreaming in the 6th Framework Programme: reference guide for scienctific officers/project officers. DG RTD, Unit 5. Women & Science, March 2003
Klinge I, Bosch M. Gender in research. Gender impact assessment of the specific programmes of the Fifth Framework Programme. Quality of life and management of living resources. Brussels: European Commission, 2001. Report No.: EUR 20017
Waals FW, Mohrs J, and Foets M. Sex differences among recipients of benzodiazepines in Dutch general practice. BMJ 1993; 307: 363–66
Blom AGTh, Paes AHP, Bakker A, et al. Drug consumption differences between men and women. Part 1 drug utilization data: part II explanations. Pharm Weekbl 1991; 126: 900–4; 924–9
Vliet K. van, Brezinska V, Lagro-Janssen T. Sex differences in the management of coronary artery disease: Evidence for gender-bias? In: Kolk A, Bekker M, van Vliet K, editors. Advances in women and health research. Towards gender sensitive strategies, Tilburg: Tilburg University Press, 1999; 85–102
Hamilton. On the inclusion of females in clinical trials in acute myocardial infarction. In: Sargent C, Bretell M, editors. Gender and health: an international perspective. New York: Prentice Hall, 1996
QLAM. Gender sensitivity in the assessment of health research by research ethics committee (REC’s). Qlam-2001-00616; 2003
European Commission. Life sciences and biotechnology: a strategy for Europe. Communication of the European Commission. Brusssels: European Commission, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klinge, I., Maguire, P. The policy implications of gender mainstreaming for healthcare research in the EU. Pharmacoeconomic 22 (Suppl 2), 87–93 (2004). https://doi.org/10.2165/00019053-200422002-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200422002-00010